The six-gate roadmap, Strategy Lock through Phase 2 Enablement, shows that the sequencing discipline built for one IND is what determines whether a company’s development engine can repeat for a second and third program.
White Paper
From IND to Phase 2: The 24 Months That Determine Whether Your Development Platform Scales
Related Resources
All Resources
case-study
Partnership with a Canadian Pharma Organization resulted in savings in effort and material cost for time-critical clinical program
Read More
case-study
Partnership helped to reduce time to market by ensuring for U.S. based virtual Biopharmaceutical company
Read More
case-study
Process improvements and in-person monitoring help U.S. pharmaceutical company achieve on time for Phase III clinical trials
Read More
post
Exploring Risk-Based Approaches to Raw Material Testing in Pharmaceutical Manufacturing
Read More
Let's move from science to success.
Let’s Talk